Squarepoint’s Elicio Therapeutics ELTX Stock Holding History

Squarepoint’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-16,662	Closed	-$133K	–	4431
2025 Q4	$133K	Buy	+16,662	New	+$151K	﹤0.01%	3985

Other funds holding ELTX

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Squarepoint's ELTX Position: Q1 2026 in Review

Squarepoint sold out of Elicio Therapeutics (ELTX) in Q1 2026, closing a stake of 16,662 shares — an estimated $133K sold.

Squarepoint first reported a position in ELTX in Q4 2025 and held it in 1 quarter. The position peaked at $133K in Q4 2025. 47 funds tracked by Wall St. Rank hold ELTX as of Q1 2026.

Squarepoint reported no remaining Elicio Therapeutics position as of Q1 2026 after selling out during the quarter.
Squarepoint sold 16,662 Elicio Therapeutics shares in Q1 2026, an estimated $133K.
Squarepoint first reported a position in Elicio Therapeutics in Q4 2025 and held it in 1 quarter.
Squarepoint's Elicio Therapeutics position peaked at $133K in Q4 2025.
47 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.